Vasodilator Therapy for Primary Pulmonary Hypertension

Harold I. Palevsky; A. P. Fishman

doi:10.1146/annurev.me.36.020185.003023

February 1, 1985Annual Review of Medicine

Vasodilator Therapy for Primary Pulmonary Hypertension

View at Publisher

Ask AI

Bookmark

Share

Key Points

Evaluate the clinical efficacy, hemodynamic effects, and safety profile of vasodilator therapies for managing primary pulmonary hypertension.
Synthesized findings from clinical investigations assessing acute and chronic vasodilator administration in pulmonary hypertensive disease.
Evaluated hemodynamic markers including mean pulmonary artery pressure, systemic vascular resistance, and cardiac index.
Vasodilators reduce pulmonary vascular resistance and augment cardiac output in a selective subgroup of responsive individuals.
Unfavorable responses including severe systemic hypotension and reflex tachycardia occur frequently, necessitating acute hemodynamic testing prior to long-term therapy.

Implication

Review evaluates vasodilator regimens in primary pulmonary hypertension, highlighting hemodynamic improvements alongside monitoring needs.

Abstract

Vasodilator Therapy for Primary Pulmonary Hypertension, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/med/36/1/annurev.me.36.020185.003023-1.gif

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Palevsky et al. (1985) studied this question.

synapsesocial.com/papers/6a926b098a638c790c5f0a30 https://doi.org/10.1146/annurev.me.36.020185.003023

View at Publisher

Ask AI

Bookmark

Share

Vasodilator Therapy for Primary Pulmonary Hypertension

Key Points

Implication

Abstract

Discussion

Cite This Study

Vasodilator Therapy for Primary Pulmonary Hypertension

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading